<ul>
<li>3 个被低估的网络安全股票，具有重大上涨潜力</li>
</ul>
<p>CapsoVision NASDAQ: CV 报告了稳定的第一季度收入，并表示继续推进人工智能和胶囊内窥镜项目，旨在扩大其胃肠成像平台的应用。</p>
<p>在公司 2026 年第一季度的财报电话会议上，总裁兼首席执行官 Johnny Wang 表示，CapsoVision 仍然专注于开发 “统一的可吞服胶囊平台”，旨在通过单一的非侵入性程序筛查多种癌症，支持这一目标的是先进的成像技术和人工智能。</p>
<ul>
<li>3 个准备反弹的软件股票</li>
</ul>
<p>“我们在第一季度继续看到稳定的良好基础表现，” Wang 说。“尽管收入和新账户的增加与去年同期保持稳定，但我们看到 CapsoCam 的使用进一步扩展，能够检测越来越多的小肠疾病。”</p>
<h2>收入保持稳定，出货量略有下降</h2>
<p>财务高级副总裁 David Garcia 表示，第一季度收入为 280 万美元，与去年同期持平。CapsoVision 在本季度出货了 6,229 个 CapsoCam Plus 胶囊，比去年同期的 6,447 个下降了 3%。</p>
<ul>
<li>隐藏的宝石：3 只价值股值得关注，预计 2025 年回报强劲</li>
</ul>
<p>Garcia 将胶囊出货量的下降归因于时机问题，表示一些较大的订单推迟到 4 月，因此被计入第二季度。他表示，单位销量的下降被平均售价的轻微上升所抵消，这反映出向高价区域的产品组合转变，而不是价格上涨。</p>
<p>截至 3 月 31 日，Garcia 表示已有超过 167,000 名患者在美国和国际市场上接受了 CapsoCam Plus 的小肠筛查成像。他还表示，CPT 代码 91110 下的报销继续支持在私人诊所和医院系统中的采用。</p>
<p>本季度的毛利润为 130 万美元，毛利率为 48%，而 2025 年第一季度为 54%。Garcia 表示，毛利率的下降主要是由于关税影响了销售成本。</p>
<p>运营费用为 840 万美元，比去年同期增加 150 万美元。增加主要是由于公司在其产品管道上的持续投资，包括与佳能的协议下与下一代成像传感器相关的开发工作，以及 CapsoCam Colon Gen Two 项目的临床试验活动。</p>
<p>CapsoVision 在本季度末拥有 1790 万美元的现金及现金等价物。Garcia 指出，公司在 3 月完成了一笔 1400 万美元的私募，得到了新老投资者的参与，他表示这为支持产品创新、临床开发和商业扩展提供了额外的灵活性。</p>
<h2>人工智能亮点预计在年中获批</h2>
<p>Wang 表示，CapsoVision 继续预计其 AI 辅助阅读能力的监管批准将在年中获得，该功能被公司命名为 AI Highlights。公司之前已提交了该功能的 510(k) 申请，并正在为获批后不久的商业发布做准备。</p>
<p>AI Highlights 旨在识别具有可疑病理的帧，并将其呈现在集成到 CapsoVision 云原生 CapsoCloud 平台中的结构化审查工作流程中。Wang 表示，医生们对最近行业会议上展示的技术反应积极，特别是其在保持临床严谨性的同时减少审查时间的潜力。</p>
<p>在电话会议的问答环节中，Titan Partners 分析师 Kyle Bauser 询问了 FDA 申请的状态。Wang 表示，公司与 FDA 在最近几个月进行了多次互动，CapsoVision 已对该机构的请求作出了回应。</p>
<p>“我们在接下来的几周内等待一次会议，” Wang 说。“据我所知，我们没有任何阻碍因素。”</p>
<h2>产品管道项目持续推进</h2>
<p>CapsoVision 表示，其 CapsoCam Colon 开发项目按计划进行，预计将在 2026 年第三季度提交其第二代胶囊和 AI 模块。Wang 表示，公司认为优先考虑第二代产品将使其能够以更具竞争力和临床差异化的产品进入市场。</p>
<p>公司还报告了其 CapsoCam UGI 项目和胰腺癌计划的进展。Wang 表示，本周开始在一项临床研究中招募患者，旨在建立诊断标准，并为潜在的非侵入性胰腺疾病筛查方法建立临床基础。</p>
<p>在回答 Bauser 的问题时，Wang 表示，该研究计划招募 120 名确诊为高等级上皮内瘤变或胰腺癌的患者，目标招募 140 名以应对可能的缺失。该研究还将包括 120 名健康对照对象，这些图像将从公司的云存储库中提取，总共 240 名受试者。</p>
<p>Wang 拒绝提供具体的招募时间表，但表示他认为胰腺研究 “比结肠研究短得多”。</p>
<h2>商业基础和前景</h2>
<p>CapsoVision 表示，在本季度与几家大型胃肠网络成功续约，包括印第安纳大学健康、普罗维登斯健康与服务和胃肠健康。Wang 表示，这些续约强化了公司平台的价值及其长期客户关系。</p>
<p>Garcia 表示，CapsoVision 继续看到来自大型胃肠网络、医院系统和团体采购组织的参与，特别是在合同到期时，提供者评估替代方案。截至季度末，公司在美国的直接销售组织包括 26 名代表，得到了七名区域销售经理和培训师的支持。在国际市场上，CapsoVision 在德国有一支专门的四人代表团队，并继续通过分销商合作伙伴扩展。</p>
<p>加西亚表示，公司预计第二季度的收入将高于第一季度，并预计下半年的收入将超过上半年。他提到了管道势头、客户参与度以及预计推出的 CapsoCam Plus 的 AI 模块。</p>
<p>在被问及运营费用时，加西亚表示对结肠研究的投资预计将持续到第三季度，并在第四季度开始减少，届时公司预计结肠研究将完成。他表示剩余费用应该相对稳定，名义增长以支持业务。加西亚还表示，全年研发支出预计将与 2025 年相似。</p>
<p>王强调，公司基于云的工作流程使 CapsoVision 能够洞察最终用户的消费和利用情况。他说：“我们可以告诉你，最终用户的消费增长是健康的。”</p>
<p>王表示，CapsoVision 仍然专注于推进一个围绕全景成像、云原生工作流程和 AI 辅助诊断构建的 AI 驱动平台。他表示，该平台允许医生在 “任何时间和地点” 安全地审查病例，而无需现场服务器或专用 IT 基础设施，同时还创建了一个基于云的数据存储库，可以支持持续的 AI 开发和培训。</p>
<h2>关于 CapsoVision NASDAQ: CV</h2>
<p>CapsoVision, Inc NASDAQ: CV 是一家专注于先进胶囊内窥镜系统的医疗设备公司，主要用于胃肠道诊断。公司的旗舰产品 CapsoCam® Plus 系统配备了一个可吞咽的、无绳胶囊，具有四个侧视摄像头，可以捕捉小肠的高分辨率 360 度图像。通过内部存储图像而不是无线传输数据，CapsoCam Plus 使患者在手术期间能够保持正常的日常活动，并减少信号丢失或图像掉落的风险。</p>
<p>除了胶囊硬件外，CapsoVision 还提供 CapsoCloud®，这是一个安全的基于云的平台，简化了图像检索、存储和报告。</p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 CapsoVision 吗？</h2>
<p>在考虑 CapsoVision 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CapsoVision 并不在名单上。</p>
<p>虽然 CapsoVision 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>CapsoVision（纳斯达克代码：CV）报告第一季度收入稳定为 280 万美元，尽管胶囊出货量略有下降，但与去年同期保持一致。该公司正在推进人工智能和胶囊内窥镜项目，计划在年中之前获得其人工智能辅助阅读能力（品牌为 AI Highlights）的监管批准。由于在产品开发上的投资，运营费用上升至 840 万美元。CapsoVision 在本季度末现金余额为 1790 万美元，并完成了 1400 万美元的私募融资，以支持创新和扩展</p>

<ul>
<li>3 Under-the-Radar Cybersecurity Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个被低估的网络安全股票，具有重大上涨潜力</li>
</ul>
</div><p>CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.</p>
<div class="lb-trans"><p>CapsoVision NASDAQ: CV 报告了稳定的第一季度收入，并表示继续推进人工智能和胶囊内窥镜项目，旨在扩大其胃肠成像平台的应用。</p>
</div><p>On the company’s first-quarter 2026 earnings call, President and Chief Executive Officer Johnny Wang said CapsoVision remains focused on developing “a unified ingestible capsule platform” intended to screen for multiple cancers through a single non-invasive procedure supported by advanced imaging and AI.</p>
<div class="lb-trans"><p>在公司 2026 年第一季度的财报电话会议上，总裁兼首席执行官 Johnny Wang 表示，CapsoVision 仍然专注于开发 “统一的可吞服胶囊平台”，旨在通过单一的非侵入性程序筛查多种癌症，支持这一目标的是先进的成像技术和人工智能。</p>
</div><ul>
<li>3 Under-the-Radar Software Stocks Ready to Bounce</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个准备反弹的软件股票</li>
</ul>
</div><p>“We continued to see consistent solid underlying performance in the first quarter,” Wang said. “While revenue and the new account additions remained stable year-over-year, we saw further expansion of CapsoCam used to detect a widening range of small bowel diseases.”</p>
<div class="lb-trans"><p>“我们在第一季度继续看到稳定的良好基础表现，” Wang 说。“尽管收入和新账户的增加与去年同期保持稳定，但我们看到 CapsoCam 的使用进一步扩展，能够检测越来越多的小肠疾病。”</p>
</div><h2>Revenue Holds Steady as Shipments Dip Slightly</h2>
<div class="lb-trans"><h2>收入保持稳定，出货量略有下降</h2>
</div><p>Senior Vice President of Finance David Garcia said first-quarter revenue was $2.8 million, consistent with the prior-year period. CapsoVision shipped 6,229 CapsoCam Plus capsules during the quarter, down 3% from 6,447 capsules in the prior-year period.</p>
<div class="lb-trans"><p>财务高级副总裁 David Garcia 表示，第一季度收入为 280 万美元，与去年同期持平。CapsoVision 在本季度出货了 6,229 个 CapsoCam Plus 胶囊，比去年同期的 6,447 个下降了 3%。</p>
</div><ul>
<li>Hidden Gems: 3 Value Stocks to Watch for Strong 2025 Returns</li>
</ul>
<div class="lb-trans"><ul>
<li>隐藏的宝石：3 只价值股值得关注，预计 2025 年回报强劲</li>
</ul>
</div><p>Garcia attributed the decline in capsule shipments to timing, saying some larger orders moved into April and were therefore placed in the second quarter. He said the lower unit volume was offset by a slight increase in average selling price, which reflected a mix shift toward higher-priced regions rather than a price increase.</p>
<div class="lb-trans"><p>Garcia 将胶囊出货量的下降归因于时机问题，表示一些较大的订单推迟到 4 月，因此被计入第二季度。他表示，单位销量的下降被平均售价的轻微上升所抵消，这反映出向高价区域的产品组合转变，而不是价格上涨。</p>
</div><p>As of March 31, Garcia said more than 167,000 patients had been imaged with CapsoCam Plus for small bowel screening across U.S. and international markets. He also said reimbursement under CPT Code 91110 continues to support adoption across private practices and hospital systems.</p>
<div class="lb-trans"><p>截至 3 月 31 日，Garcia 表示已有超过 167,000 名患者在美国和国际市场上接受了 CapsoCam Plus 的小肠筛查成像。他还表示，CPT 代码 91110 下的报销继续支持在私人诊所和医院系统中的采用。</p>
</div><p>Gross profit for the quarter was $1.3 million, with gross margin of 48%, compared with 54% in the first quarter of 2025. Garcia said the margin decline was primarily due to tariffs affecting cost of goods sold.</p>
<div class="lb-trans"><p>本季度的毛利润为 130 万美元，毛利率为 48%，而 2025 年第一季度为 54%。Garcia 表示，毛利率的下降主要是由于关税影响了销售成本。</p>
</div><p>Operating expenses were $8.4 million, up $1.5 million from the prior-year period. The increase was primarily driven by continued investment in the company’s pipeline, including development work tied to a next-generation imaging sensor under its agreement with Canon and clinical trial activity for the CapsoCam Colon Gen Two program.</p>
<div class="lb-trans"><p>运营费用为 840 万美元，比去年同期增加 150 万美元。增加主要是由于公司在其产品管道上的持续投资，包括与佳能的协议下与下一代成像传感器相关的开发工作，以及 CapsoCam Colon Gen Two 项目的临床试验活动。</p>
</div><p>CapsoVision ended the quarter with $17.9 million in cash and cash equivalents. Garcia noted that the company closed a $14 million private placement in March with participation from new and existing investors, which he said provides added flexibility to support product innovation, clinical development and commercial expansion.</p>
<div class="lb-trans"><p>CapsoVision 在本季度末拥有 1790 万美元的现金及现金等价物。Garcia 指出，公司在 3 月完成了一笔 1400 万美元的私募，得到了新老投资者的参与，他表示这为支持产品创新、临床开发和商业扩展提供了额外的灵活性。</p>
</div><h2>AI Highlights Clearance Expected Around Mid-Year</h2>
<div class="lb-trans"><h2>人工智能亮点预计在年中获批</h2>
</div><p>Wang said CapsoVision continues to expect regulatory clearance around mid-year for its AI-assisted reading capability for CapsoCam Plus, which the company has branded AI Highlights. The company previously submitted a 510(k) application for the feature and is preparing for a commercial launch shortly after clearance.</p>
<div class="lb-trans"><p>Wang 表示，CapsoVision 继续预计其 AI 辅助阅读能力的监管批准将在年中获得，该功能被公司命名为 AI Highlights。公司之前已提交了该功能的 510(k) 申请，并正在为获批后不久的商业发布做准备。</p>
</div><p>AI Highlights is designed to identify frames with suspected pathology and present them in a structured review workflow integrated into CapsoVision’s cloud-native CapsoCloud platform. Wang said physicians have responded positively to demonstrations of the technology at recent industry meetings, particularly its potential to reduce review time while maintaining clinical rigor.</p>
<div class="lb-trans"><p>AI Highlights 旨在识别具有可疑病理的帧，并将其呈现在集成到 CapsoVision 云原生 CapsoCloud 平台中的结构化审查工作流程中。Wang 表示，医生们对最近行业会议上展示的技术反应积极，特别是其在保持临床严谨性的同时减少审查时间的潜力。</p>
</div><p>During the question-and-answer portion of the call, Titan Partners analyst Kyle Bauser asked about the status of the FDA application. Wang said the company and the FDA had several interactions in recent months, and that CapsoVision had responded to the agency’s requests.</p>
<div class="lb-trans"><p>在电话会议的问答环节中，Titan Partners 分析师 Kyle Bauser 询问了 FDA 申请的状态。Wang 表示，公司与 FDA 在最近几个月进行了多次互动，CapsoVision 已对该机构的请求作出了回应。</p>
</div><p>“We are waiting for a meeting in the next few weeks,” Wang said. “We have no showstoppers to my knowledge.”</p>
<div class="lb-trans"><p>“我们在接下来的几周内等待一次会议，” Wang 说。“据我所知，我们没有任何阻碍因素。”</p>
</div><h2>Pipeline Programs Continue to Advance</h2>
<div class="lb-trans"><h2>产品管道项目持续推进</h2>
</div><p>CapsoVision said its CapsoCam Colon development program remains on track, with submission of its second-generation capsule and AI module expected in the third quarter of 2026. Wang said the company believes prioritizing the second-generation product positions it to enter the market with a more competitive and clinically differentiated offering.</p>
<div class="lb-trans"><p>CapsoVision 表示，其 CapsoCam Colon 开发项目按计划进行，预计将在 2026 年第三季度提交其第二代胶囊和 AI 模块。Wang 表示，公司认为优先考虑第二代产品将使其能够以更具竞争力和临床差异化的产品进入市场。</p>
</div><p>The company also reported progress in its CapsoCam UGI program and pancreatic cancer initiative. Wang said enrollment began this week in a clinical study intended to establish diagnostic criteria and build a clinical foundation for a potential non-invasive screening approach for pancreatic disease.</p>
<div class="lb-trans"><p>公司还报告了其 CapsoCam UGI 项目和胰腺癌计划的进展。Wang 表示，本周开始在一项临床研究中招募患者，旨在建立诊断标准，并为潜在的非侵入性胰腺疾病筛查方法建立临床基础。</p>
</div><p>In response to a question from Bauser, Wang said the study is planned to enroll 120 patients with confirmed high-grade dysplasia or pancreatic cancer, with a target enrollment of 140 to account for possible dropouts. The study will also include 120 healthy reference subjects, with those images pulled from the company’s cloud storage repository, for a total of 240 subjects.</p>
<div class="lb-trans"><p>在回答 Bauser 的问题时，Wang 表示，该研究计划招募 120 名确诊为高等级上皮内瘤变或胰腺癌的患者，目标招募 140 名以应对可能的缺失。该研究还将包括 120 名健康对照对象，这些图像将从公司的云存储库中提取，总共 240 名受试者。</p>
</div><p>Wang declined to provide a specific enrollment timeline but said he viewed the pancreatic study as “a much shorter study than colon.”</p>
<div class="lb-trans"><p>Wang 拒绝提供具体的招募时间表，但表示他认为胰腺研究 “比结肠研究短得多”。</p>
</div><h2>Commercial Base and Outlook</h2>
<div class="lb-trans"><h2>商业基础和前景</h2>
</div><p>CapsoVision said it secured renewals during the quarter with several large gastrointestinal networks, including Indiana University Health, Providence Health &amp; Services and Gastro Health. Wang said those renewals reinforce the value of the company’s platform and its long-term customer relationships.</p>
<div class="lb-trans"><p>CapsoVision 表示，在本季度与几家大型胃肠网络成功续约，包括印第安纳大学健康、普罗维登斯健康与服务和胃肠健康。Wang 表示，这些续约强化了公司平台的价值及其长期客户关系。</p>
</div><p>Garcia said CapsoVision continues to see engagement from larger gastroenterology networks, hospital systems and group purchasing organizations, particularly as contracts come up for renewal and providers evaluate alternatives. As of quarter end, the company’s U.S. direct sales organization included 26 representatives, supported by seven regional sales managers and trainers. Internationally, CapsoVision has a dedicated team of four representatives in Germany and continues to expand through distributor partnerships.</p>
<div class="lb-trans"><p>Garcia 表示，CapsoVision 继续看到来自大型胃肠网络、医院系统和团体采购组织的参与，特别是在合同到期时，提供者评估替代方案。截至季度末，公司在美国的直接销售组织包括 26 名代表，得到了七名区域销售经理和培训师的支持。在国际市场上，CapsoVision 在德国有一支专门的四人代表团队，并继续通过分销商合作伙伴扩展。</p>
</div><p>Garcia said the company expects second-quarter revenue to be higher than first-quarter revenue and expects revenue in the second half of the year to exceed first-half revenue. He cited pipeline momentum, customer engagement and the anticipated launch of the AI module for CapsoCam Plus.</p>
<div class="lb-trans"><p>加西亚表示，公司预计第二季度的收入将高于第一季度，并预计下半年的收入将超过上半年。他提到了管道势头、客户参与度以及预计推出的 CapsoCam Plus 的 AI 模块。</p>
</div><p>Asked about operating expenses, Garcia said investment in the colon study is expected to continue through the third quarter and begin trailing off in the fourth quarter, when the company expects the colon study to be completed. He said remaining expenses should be fairly stable, with nominal growth to support the business. Garcia also said full-year research and development spending is expected to be similar to 2025.</p>
<div class="lb-trans"><p>在被问及运营费用时，加西亚表示对结肠研究的投资预计将持续到第三季度，并在第四季度开始减少，届时公司预计结肠研究将完成。他表示剩余费用应该相对稳定，名义增长以支持业务。加西亚还表示，全年研发支出预计将与 2025 年相似。</p>
</div><p>Wang emphasized that the company’s cloud-based workflow gives CapsoVision visibility into end-user consumption and utilization. “We can tell you the end user consumption growth is healthy,” he said.</p>
<div class="lb-trans"><p>王强调，公司基于云的工作流程使 CapsoVision 能够洞察最终用户的消费和利用情况。他说：“我们可以告诉你，最终用户的消费增长是健康的。”</p>
</div><p>Wang said CapsoVision remains focused on advancing an AI-enabled platform built around panoramic imaging, cloud-native workflow and AI-assisted diagnostics. He said the platform allows physicians to securely review cases “anytime and anywhere” without on-site servers or dedicated IT infrastructure, while also creating a cloud-based data repository that could support continued AI development and training over time.</p>
<div class="lb-trans"><p>王表示，CapsoVision 仍然专注于推进一个围绕全景成像、云原生工作流程和 AI 辅助诊断构建的 AI 驱动平台。他表示，该平台允许医生在 “任何时间和地点” 安全地审查病例，而无需现场服务器或专用 IT 基础设施，同时还创建了一个基于云的数据存储库，可以支持持续的 AI 开发和培训。</p>
</div><h2>About CapsoVision NASDAQ: CV</h2>
<div class="lb-trans"><h2>关于 CapsoVision NASDAQ: CV</h2>
</div><p>CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.</p>
<div class="lb-trans"><p>CapsoVision, Inc NASDAQ: CV 是一家专注于先进胶囊内窥镜系统的医疗设备公司，主要用于胃肠道诊断。公司的旗舰产品 CapsoCam® Plus 系统配备了一个可吞咽的、无绳胶囊，具有四个侧视摄像头，可以捕捉小肠的高分辨率 360 度图像。通过内部存储图像而不是无线传输数据，CapsoCam Plus 使患者在手术期间能够保持正常的日常活动，并减少信号丢失或图像掉落的风险。</p>
</div><p>In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.</p>
<div class="lb-trans"><p>除了胶囊硬件外，CapsoVision 还提供 CapsoCloud®，这是一个安全的基于云的平台，简化了图像检索、存储和报告。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CapsoVision Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 CapsoVision 吗？</h2>
</div><p>Before you consider CapsoVision, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CapsoVision 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CapsoVision wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 CapsoVision 并不在名单上。</p>
</div><p>While CapsoVision currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CapsoVision 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CapsoVision 第一季度财报电话会议亮点